$GNPX
Genprex Inc

2022 Q1 Form 10-Q Financial Statement

#000143774922012372 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.856M $2.196M $4.320M
YoY Change -10.75% -24.29% 5.62%
% of Gross Profit
Research & Development $1.861M $3.480M $2.169M
YoY Change -14.21% 50.01% 46.77%
% of Gross Profit
Depreciation & Amortization $6.730K $6.950K $6.242K
YoY Change 7.82% 16.61%
% of Gross Profit
Operating Expenses $1.861M $5.683M $2.169M
YoY Change -14.21% 8.66% 46.77%
Operating Profit -$5.723M -$6.492M
YoY Change -11.84% 16.42%
Interest Expense $880.00 $990.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.722M -$5.682M -$6.490M
YoY Change -11.83% 8.64% 16.52%
Income Tax
% Of Pretax Income
Net Earnings -$5.722M -$5.682M -$6.490M
YoY Change -11.82% 8.64% 16.59%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.14
Diluted Earnings Per Share -$119.5K -$118.8K -$142.5K
COMMON SHARES
Basic Shares Outstanding 47.88M 47.81M 45.55M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.56M $38.63M $47.07M
YoY Change -26.59% 41.39% 103.94%
Cash & Equivalents $34.56M $38.63M $47.07M
Short-Term Investments
Other Short-Term Assets $1.116M $511.4K $200.0K
YoY Change 457.8% 34.57% 185.71%
Inventory $3.110M
Prepaid Expenses
Receivables $32.17K $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.70M $39.14M $50.38M
YoY Change -29.13% 41.28% 109.63%
LONG-TERM ASSETS
Property, Plant & Equipment $41.88K $48.61K $37.30K
YoY Change 12.27% 23.24% -26.45%
Goodwill
YoY Change
Intangibles $644.2K $642.4K $610.7K
YoY Change 5.49% 6.77% 13.95%
Long-Term Investments
YoY Change
Other Assets $3.664M $3.673M $621.4K
YoY Change 489.67% 1.38% 11.43%
Total Long-Term Assets $3.706M $3.722M $658.7K
YoY Change 462.64% 1.62% 8.28%
TOTAL ASSETS
Total Short-Term Assets $35.70M $39.14M $50.38M
Total Long-Term Assets $3.706M $3.722M $658.7K
Total Assets $39.41M $42.86M $51.04M
YoY Change -22.78% 36.65% 107.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.253M $973.2K $340.0K
YoY Change 268.52% 412.21% -46.88%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.385M $1.585M $613.6K
YoY Change 288.64% 251.72% -11.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.385M $1.585M $613.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.385M $1.585M $610.0K
YoY Change 290.95% 252.29% -12.86%
SHAREHOLDERS EQUITY
Retained Earnings -$83.74M -$78.02M -$64.91M
YoY Change 29.01% 33.54% 40.97%
Common Stock $47.88K $47.87K $47.32K
YoY Change 1.19% 11.03% 44.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.02M $41.28M $50.42M
YoY Change
Total Liabilities & Shareholders Equity $39.41M $42.86M $51.04M
YoY Change -22.78% 36.65% 107.13%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$5.722M -$5.682M -$6.490M
YoY Change -11.82% 8.64% 16.59%
Depreciation, Depletion And Amortization $6.730K $6.950K $6.242K
YoY Change 7.82% 16.61%
Cash From Operating Activities -$4.084M -$3.218M -$5.465M
YoY Change -25.28% -17.49% 20.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$26.22K $91.70K
YoY Change -100.0% 31.1% 703.55%
Acquisitions
YoY Change
Other Investing Activities $12.16K -$147.4K -$10.00K
YoY Change -221.6% -93.68% -87.5%
Cash From Investing Activities $10.32K -$173.6K -$110.0K
YoY Change -109.38% -92.58% -19.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $25.32M
YoY Change -100.0% -1.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 0.000 $25.32M
YoY Change -100.0% -100.0% -1.58%
NET CHANGE
Cash From Operating Activities -$4.084M -3.218M -$5.465M
Cash From Investing Activities $10.32K -173.6K -$110.0K
Cash From Financing Activities $0.00 0.000 $25.32M
Net Change In Cash -$4.074M -3.392M $19.75M
YoY Change -120.63% -154.18% -6.3%
FREE CASH FLOW
Cash From Operating Activities -$4.084M -$3.218M -$5.465M
Capital Expenditures $0.00 -$26.22K $91.70K
Free Cash Flow -$4.084M -$3.192M -$5.557M
YoY Change -26.51% -17.74% 22.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47898351
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47879708
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47879708
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47874708
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47874708
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34555337 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38628876 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32171 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1115601 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
511348 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
35703109 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
39140224 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41878 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48608 USD
CY2022Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10000 USD
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8691 USD
CY2022Q1 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
3010243 USD
CY2021Q4 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
3022403 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
644201 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
642360 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3664444 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3673454 USD
CY2022Q1 us-gaap Assets
Assets
39409431 USD
CY2021Q4 us-gaap Assets
Assets
42862286 USD
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1252978 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
973195 USD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1131839 USD
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
612100 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2384817 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1585295 USD
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
47879 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47874 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
120717072 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119246970 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83740337 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78017853 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37024614 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41276991 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39409431 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42862286 USD
CY2022Q1 us-gaap Revenues
Revenues
0 USD
CY2021Q1 us-gaap Revenues
Revenues
0 USD
CY2022Q1 us-gaap Depreciation
Depreciation
6730 USD
CY2021Q1 us-gaap Depreciation
Depreciation
6242 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1860837 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2169143 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3855796 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4316310 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
5723363 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
6491695 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5723363 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6491695 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
879 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1982 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5722484 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6489713 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47879597
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45546106
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25324330 USD
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20650 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
651088 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6489713 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
50422845 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41276991 USD
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
17500 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1452607 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5722484 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37024614 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5722484 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6489713 USD
CY2022Q1 us-gaap Depreciation
Depreciation
6730 USD
CY2021Q1 us-gaap Depreciation
Depreciation
6242 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1470107 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
671738 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32171 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
605561 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-187282 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
279783 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
146493 USD
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
519739 USD
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
12676 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4083857 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5465282 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
91701 USD
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1841 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9071 USD
CY2022Q1 gnpx Payments For Proceeds From Research And Development Supplies
PaymentsForProceedsFromResearchAndDevelopmentSupplies
-12160 USD
CY2021Q1 gnpx Payments For Proceeds From Research And Development Supplies
PaymentsForProceedsFromResearchAndDevelopmentSupplies
9258 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10319 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110030 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25324330 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25324330 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38628876 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27319685 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4073539 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19749018 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34555337 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47068703 USD
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
34178486 USD
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
38392886 USD
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5000
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
17500 USD
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
670889
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
677912 USD
CY2021 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
86138
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
156045 USD
CY2022Q1 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3010243 USD
CY2021Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3022403 USD
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47879708
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2154747
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.37
CY2021 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
50000
CY2021 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
5.29
CY2021 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
-0
CY2021 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0
CY2021 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-0
CY2021 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2204747
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.39
CY2022Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0
CY2022Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
CY2022Q1 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
-0
CY2022Q1 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0
CY2022Q1 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-0
CY2022Q1 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2204747
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.39
CY2022Q1 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
0
CY2022Q1 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
0
CY2022Q1 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
1971412
CY2022Q1 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.62
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10961363
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2404562
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17500
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.00
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2519628
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
118507
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
670889
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M9D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6844069
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2519628
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.26
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
670889
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.01
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
118507
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8574301
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.35
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2404562
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.30
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17500
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.00
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10961363
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.13
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
605648
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.45
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5981155
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.20
CY2022Q1 us-gaap Other Commitment
OtherCommitment
340000 USD

Files In Submission

Name View Source Status
0001437749-22-012372-index-headers.html Edgar Link pending
0001437749-22-012372-index.html Edgar Link pending
0001437749-22-012372.txt Edgar Link pending
0001437749-22-012372-xbrl.zip Edgar Link pending
ex_342874.htm Edgar Link pending
ex_342875.htm Edgar Link pending
ex_342876.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20220331.xsd Edgar Link pending
gnpx-20220331_cal.xml Edgar Link unprocessable
gnpx-20220331_def.xml Edgar Link unprocessable
gnpx-20220331_lab.xml Edgar Link unprocessable
gnpx-20220331_pre.xml Edgar Link unprocessable
gnpx20220331_10q.htm Edgar Link pending
gnpx20220331_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending